Abstract:Question Is there an association between Notch homolog 2 N-terminal-like C (NOTCH2NLC) GGC repeats and Parkinson disease (PD)?Findings A genetic screening of NOTCH2NLC GGC repeat expansion was carried out in a cohort of 1000 patients with sporadic PD and 1076 healthy control participants. A total of 13 patients with PD were identified as carrying NOTCH2NLC GGC repeat expansions greater than 40 units, and no repeat expansions were detected in healthy control participants (P < .001).Meaning Per this analysis, individuals with sporadic PD who carried pathogenic NOTCH2NLC GGC repeat expansions (>79 repeats) can present with typical PD, requiring low levodopa dosages, with no other clinical or imaging features of neuronal intranuclear inclusion body disease even after several years of follow-up.Importance The presence of Notch homolog 2 N-terminal-like C (NOTCH2NLC) repeat expansions are associated with neuronal intranuclear inclusion body disease (NIID), with varied neurological signs, including neuropathy, ataxia, parkinsonism, and tremor. To date, genetic screening of NOTCH2NLC GGC repeats in a cohort with typical Parkinson disease (PD) appears not to have been reported.Objective To investigate if NOTCH2NLC GGC expansions are present in a cohort of patients with PD and controls.Design, Setting, and Participants This case-control study was conducted in 2 tertiary movement disorder centers in Singapore. Participants were recruited and followed up from January 2005 to January 2020. The presence of NOTCH2NLC GGC expansion repeats was screened using polymerase chain reaction tests, and representative samples were verified with long-read genome sequencing.Main Outcomes and Measures Qualitative and quantitative comparisons between participants with sporadic PD, healthy control participants, and individuals with NIID.Results A total of 2076 participants, including 1000 with sporadic PD (600 men [60.0%]; mean age at onset, 62.6 [7.7] years) and 1076 healthy controls (581 men [54.0%]; mean age at study recruitment, 54.9 [9.4] years) were recruited. A total of 13 patients with PD and no healthy control participants were identified as carrying NOTCH2NLC GGC repeat expansions of more than 40 units; the frequency of more than 40 repeat expansions was higher in participants with PD than controls (P < .001). None of the patients with PD were carriers of known PD-associated genes. Ten patients with PD carried a GGC expansion of between 41 and 64 repeats (1% of patients with sporadic PD; mean [SD], 49.4 [9.2] repeats). The other 3 patients carried GGC repeats of 79 or more units, 2 with 122 and 79 repeats, respectively, exhibited typical parkinsonism and were responsive to small dosages of levodopa over many years, with no clinical or imaging features of NIID. The other patient with PD, who had 130 repeats, only developed cognitive impairment before death. Within the GGC expansions, there was no GGA interruptions (mean [SD] GGA percentage in the 3 patients with PD vs patients with NIID, 0% vs 12% [9%]), and the frequency of AGC interruptions was 3 times higher in these patients with PD than patients with NIID (mean [SD], 25% [12%] vs 8% [8%]).Conclusions and Relevance This study demonstrated that individuals with sporadic PD who carried pathogenic NOTCH2NLC GGC repeat expansions can present with typical parkinsonism, requiring only low dosages of levodopa, without displaying other clinical or imaging features of NIID even after several years of follow-up. None of the patients with PD had GGA interruptions within their GGC expansions, and the frequency of AGC interruptions was much higher than that of patients with NIID. The functional significance of a higher moderate repeat expansion in patients with PD compared with healthy controls needs to be further investigated.

NOTCH2NLC GGC intermediate repeat with serine induces hypermyelination and early Parkinson's disease-like phenotypes in mice

The role of NOTCH2NLC in Parkinson's disease: A clinical, neuroimaging, and pathological study

NOTCH2NLC-related Repeat Expansion Disorders: an Expanding Group of Neurodegenerative Disorders

Expression of expanded GGC repeats within NOTCH2NLC causes behavioral deficits and neurodegeneration in a mouse model of neuronal intranuclear inclusion disease

GGC Repeat Expansion in NOTCH2NLC Induces Dysfunction in Ribosome Biogenesis and Translation.

GGC expansions in NOTCH2NLC contribute to Parkinson disease and dopaminergic neuron degeneration

NOTCH2NLC Intermediate‐Length Repeat Expansions Are Associated with Parkinson Disease

Neuronal Intranuclear Inclusion Disease Tremor-Dominant Subtype: A Mimicker of Essential Tremor

Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders.

Association of NOTCH2NLC Repeat Expansions With Parkinson Disease

Intermediate-Length GGC Repeat Expansion in NOTCH2NLC Was Identified in Chinese Patients with Amyotrophic Lateral Sclerosis

Identification of GGC Repeat Expansion in the NOTCH2NLC Gene in Amyotrophic Lateral Sclerosis

Upstream open reading frame with NOTCH2NLC GGC expansion generates polyglycine aggregates and disrupts nucleocytoplasmic transport: implications for polyglycine diseases

Expression of expanded GGC repeats within NOTCH2NLC causes cardiac dysfunction in mouse models

NOTCH2NLC expanded GGC repeats in patients with cerebral small vessel disease

Long-read sequencing identified repeat expansions in the 5′UTR of the NOTCH2NLC gene from Chinese patients with neuronal intranuclear inclusion disease

Intermediate-length CGG repeat expansion in NOTCH2NLC is associated with pathologically confirmed Alzheimer's disease

GGC repeat expansions in NOTCH2NLC causing a phenotype of distal motor neuropathy and myopathy

CGG Repeat Expansion in NOTCH2NLC Causes Mitochondrial Dysfunction and Progressive Neurodegeneration in Drosophila Model.

Clinical features of NOTCH2NLC-related neuronal intranuclear inclusion disease

Genetic Origin of Sporadic Cases and RNA Toxicity in Neuronal Intranuclear Inclusion Disease